SHSE:603014 (China)
Â
Ord Shares- Class A
Â¥
30.79
-0.34 (-1.09%)
Sep 11
Business Description
Shandong Weigao Blood Purification Products Co Ltd
ISIN : CNE100007093
Share Class Description:
SHSE:603014: Ord Shares- Class ATotal Employee Number:
3,734Compare
Compare
Traded in other countries / regions
603014.China Index Membership
SSE Composite Index IPO Date
2025-05-19Description
Shandong Weigao Blood Purification Products Co Ltd engaged in research and development, production and sales of blood purification medical products.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 128.18 | |||||
Equity-to-Asset | 0.85 | |||||
Debt-to-EBITDA | 0.04 | |||||
Interest Coverage | 547.35 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 7.67 | |||||
Beneish M-Score | -2.57 | |||||
WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 0.2 | |||||
3-Year EBITDA Growth Rate | 4.6 | |||||
3-Year EPS without NRI Growth Rate | 7.7 | |||||
3-Year FCF Growth Rate | 9.1 | |||||
3-Year Book Growth Rate | 10.6 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 9.76 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 8.88 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 24.12 | |||||
9-Day RSI | 30.08 | |||||
14-Day RSI | 35.73 | |||||
3-1 Month Momentum % | 1.6 | |||||
6-1 Month Momentum % | -12.95 | |||||
12-1 Month Momentum % | -16.44 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.89 | |||||
Quick Ratio | 3.15 | |||||
Cash Ratio | 2.31 | |||||
Days Inventory | 128.85 | |||||
Days Sales Outstanding | 83.93 | |||||
Days Payable | 83.26 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 1.68 | |||||
Dividend Payout Ratio | 0.43 | |||||
Forward Dividend Yield % | 1.85 | |||||
5-Year Yield-on-Cost % | 1.68 | |||||
3-Year Average Share Buyback Ratio | -4.1 | |||||
Shareholder Yield % | 1.66 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 38.72 | |||||
Operating Margin % | 15.04 | |||||
Net Margin % | 13.07 | |||||
EBITDA Margin % | 15.33 | |||||
FCF Margin % | 14.9 | |||||
OCF Margin % | 19.5 | |||||
ROE % | 6.95 | |||||
ROA % | 5.82 | |||||
ROIC % | 9.86 | |||||
3-Year ROIIC % | 46.46 | |||||
ROC (Joel Greenblatt) % | 15.18 | |||||
ROCE % | 8.06 | |||||
Years of Profitability over Past 10-Year | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 25.87 | |||||
Forward PE Ratio | 22.26 | |||||
PE Ratio without NRI | 25.49 | |||||
Price-to-Owner-Earnings | 41.71 | |||||
PEG Ratio | 6.22 | |||||
PS Ratio | 3.37 | |||||
PB Ratio | 1.78 | |||||
Price-to-Tangible-Book | 1.85 | |||||
Price-to-Free-Cash-Flow | 22.23 | |||||
Price-to-Operating-Cash-Flow | 17.14 | |||||
EV-to-EBIT | 17.71 | |||||
EV-to-EBITDA | 17.71 | |||||
EV-to-Revenue | 2.71 | |||||
EV-to-FCF | 18.22 | |||||
Price-to-Graham-Number | 1.45 | |||||
| Price-to-Net-Current-Asset-Value | 3.95 | |||||
| Price-to-Net-Cash | 8.98 | |||||
Earnings Yield (Greenblatt) % | 5.65 | |||||
FCF Yield % | 4.36 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Shandong Weigao Blood Purification Products Co Ltd Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 3,762.283 | ||
| EPS (TTM) (Â¥) | 1.19 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 12.77 | ||
| 14-Day RSI | 35.73 | ||
| 14-Day ATR (Â¥) | 0.728984 | ||
| 20-Day SMA (Â¥) | 32.012 | ||
| 12-1 Month Momentum % | -16.44 | ||
| 52-Week Range (Â¥) | 29.7 - 49.01 | ||
| Shares Outstanding (Mil) | 417.75 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Shandong Weigao Blood Purification Products Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Shandong Weigao Blood Purification Products Co Ltd Stock Events
| Event | Date | Price (Â¥) | ||
|---|---|---|---|---|
| CNY 0.210000 Cash Dividend | 2026-09-14 | In 1 day | ||
| CNY 0.360800 Cash Dividend | 2026-06-01 | 35.41 (-1.64%) | ||
| CNY 0.157560 Cash Dividend | 2025-10-24 | 38.61 (+0.00%) |
Show
Entries
Shandong Weigao Blood Purification Products Co Ltd Frequently Asked Questions
What is Shandong Weigao Blood Purification Products Co Ltd(SHSE:603014)'s stock price today?
The current price of SHSE:603014 is ¥30.79. The 52 week high of SHSE:603014 is ¥49.01 and 52 week low is ¥29.70.
When is next earnings date of Shandong Weigao Blood Purification Products Co Ltd(SHSE:603014)?
The next earnings date of Shandong Weigao Blood Purification Products Co Ltd(SHSE:603014) is .
Does Shandong Weigao Blood Purification Products Co Ltd(SHSE:603014) pay dividends? If so, how much?
The Dividend Yield %  of Shandong Weigao Blood Purification Products Co Ltd(SHSE:603014) is 1.68% (As of Today), Highest Dividend Payout Ratio of Shandong Weigao Blood Purification Products Co Ltd(SHSE:603014) was 0.43. The lowest was 0.14. And the median was 0.14. The  Forward Dividend Yield % of Shandong Weigao Blood Purification Products Co Ltd(SHSE:603014) is 1.85%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers